

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company

limited by guarantee and not having a share capital)

STATUTORY FINANCIAL STATEMENTS

31 DECEMBER 2013

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES

Tunku Tan Sri Dato' Seri Ahmad bin Tunku Yahaya

Toh Puan Dato' Seri Hajah Dr Aishah Ong

Lim Siew Lian

Abd. Hamid bin Ibrahim

Tengku Datuk Seri Ahmad Shah Al-Haj Ibni Almarhum Sultan Salahuddin Abdul Aziz Shah Al-Haj

Alan Hamzah Sendut

Dato' Dr Ir Gan Thian Leong

Dato' Leong Kwei Chun

SECRETARY

Noor Zita binti Hassan

AUDITORS

PricewaterhouseCoopers

REGISTERED OFFICE

1st Floor Lot 33

Jalan Pelukis U1/46

Temasya Industrial Park

Seksyen U1

40150 Shah Alam

Selangor Darul Ehsan

Malaysia

PRINCIPAL PLACE OF BUSINESS

2nd Floor, Outpatient Centre

Sime Darby Medical Centre Subang Jaya

47500 Subang Jaya

Selangor Darul Ehsan

Malaysia

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

CONTENTS	PAGES
TRUSTEES' REPORT	1 - 3
FINANCIAL STATEMENTS	
INCOME AND EXPENDITURE STATEMENTS	4
STATEMENTS OF FINANCIAL POSITION	5
STATEMENTS OF CHANGES IN GENERAL FUNDS	6
STATEMENTS OF CASH FLOWS	7
NOTES TO THE FINANCIAL STATEMENTS	8 - 25
STATEMENT BY TRUSTEES	26
STATUTORY DECLARATION	26
INDEPENDENT AUDITORS' REPORT	27 - 28

Company No.

510087	M
--------	---

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company

limited by guarantee and not having a share capital)

TRUSTEES' REPORT

The Trustees are pleased to submit their report together with the audited financial statements of Economic Entity and of the Foundation for the financial year ended 31 December 2013.

PRINCIPAL ACTIVITY

The principal activity of the Foundation is to receive and administer funds for cancer research purposes. There have been no significant changes in the nature of this activity during the financial year.

The Foundation's joint venture is principally involved in rendering of services and products based in cell biology and cell culture technology.

The Foundation is incorporated in Malaysia as a company limited by guarantee and does not have a share capital.

FINANCIAL RESULTS

	<u>Economic Entity</u> RM	<u>Foundation</u> RM
Excess of income over expenditure for the financial year	2,773,166	2,773,166

RESERVES AND PROVISIONS

There were no material transfers to or from reserves and provisions during the financial year.

BOARD OF TRUSTEES

The members of the Board of Trustees who have held office during the period since the date of the last report are as follows:

Tunku Tan Sri Dato' Seri Ahmad bin Tunku Yahaya
Toh Puan Dato' Seri Hajah Dr Aishah Ong
Lim Siew Lian
Abd. Hamid bin Ibrahim
Tengku Datuk Seri Ahmad Shah
Al-Haj Ibni Almarhum Sultan Salahuddin Abdul
Aziz Shah Al-Haj
Alan Hamzah Sendut
Dato' Dr Ir Gan Thian Leong
Dato' Leong Kwei Chun (appointed on 13 March 2014)

Tunku Tan Sri Dato' Seri Ahmad bin Tunku Yahaya, being over seventy years of age, retires in accordance with Section 129 of the Companies Act, 1965 and offers himself for re-appointment in accordance with Section 129(6) of the Act to hold office until the conclusion of the next Annual General Meeting of the Foundation.

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES' REPORT (CONTINUED)

BOARD OF TRUSTEES (CONTINUED)

Tengku Datuk Seri Ahmad Shah Al-Haj ibni Almarhum Sultan Salahuddin Abdul Aziz Shah Al-Haj, Alan Hamzah Sendut and Dato' Dr Ir Gan Thian Leong who retire by rotation in accordance with the Articles of Association of the Foundation at the forthcoming Annual General Meeting and, being eligible, offer themselves for re-election.

TRUSTEES' BENEFITS

During and at the end of the financial year, no arrangements subsisted to which the Foundation is a party, being arrangements with the object or objects of enabling the Trustees of the Foundation to acquire benefits by means of the acquisition of shares in, or debentures of, the Foundation or any other body corporate.

Since the end of the previous financial year, no Trustee of the Foundation has received or become entitled to receive a benefit by reason of a contract made by the Foundation or a related corporation with the Trustee or with a firm of which the Trustee is a member, or with a company in which the Trustee has a substantial interest.

STATUTORY INFORMATION ON THE FINANCIAL STATEMENTS

Before the financial statements were made out, the Trustees took reasonable steps:

- (a) to ascertain that proper action had been taken in relation to the writing off of bad debts and the making of allowance for doubtful debts and satisfied themselves that all known bad debts had been written off and that adequate allowance had been made for doubtful debts; and
- (b) to ensure that any current assets, which were unlikely to realise in the ordinary course of business, their values as shown in the accounting records of the Economic Entity and of the Foundation have been written down to an amount which they might be expected so to realise.

At the date of this report, the Trustees are not aware of any circumstances:

- (a) which would render the amounts written off for bad debts or the amount of allowance for doubtful debts in the financial statements of the Economic Entity and of the Foundation inadequate to any substantial extent; or
- (b) which would render the values attributed to current assets in the financial statements of the Economic Entity and of the Foundation misleading; or
- (c) which have arisen which render adherence to the existing method of valuation of assets or liabilities of the Economic Entity and of the Foundation misleading or inappropriate.

No contingent or other liability has become enforceable or is likely to become enforceable within the period of twelve months after the end of the financial year which, in the opinion of the Trustees, will or may substantially affect the ability of the Economic Entity and of the Foundation to meet their obligations when they fall due.

Company No.

510087	M
--------	---

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

TRUSTEES' REPORT (CONTINUED)

STATUTORY INFORMATION ON THE FINANCIAL STATEMENTS (CONTINUED)

At the date of this report, there does not exist:

- (a) any charge on the assets of the Economic Entity and of the Foundation which has arisen since the end of the financial year which secures the liability of any other person; or
- (b) any contingent liability of the Economic Entity and of the Foundation which has arisen since the end of the financial year.

At the date of this report, the Trustees are not aware of any circumstances not otherwise dealt with in this report or the financial statements which would render any amount stated in the financial statements misleading.


In the opinion of the Trustees:

- (a) the results of the Economic Entity's and of the Foundation's operations during the financial year were not substantially affected by any item, transaction or event of a material and unusual nature; and
- (b) there has not arisen in the interval between the end of the financial year and the date of this report any item, transaction or event of a material and unusual nature that is likely to affect substantially the results of the operations of the Economic Entity and of the Foundation for the financial year in which this report is made.


AUDITORS

The auditors, PricewaterhouseCoopers, have expressed their willingness to continue in office.

In accordance with the resolution of the Board of Trustees dated 22 May 2014.



TUNKU TAN SRI DATO' SERI AHMAD
BIN TUNKU YAHAYA
TRUSTEE



TOH PUAN DATO' SERI HAJAH
DR AISHAH ONG
TRUSTEE

Kuala Lumpur
22 May 2014

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company limited by guarantee and not having a share capital)

INCOME AND EXPENDITURE STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013

	Note	Economic Entity		Foundation	
		2013 RM	2012 RM	2013 RM	2012 RM
INCOME					
Donations		6,682,015	7,276,367	6,682,015	7,276,367
Research grants		502,200	514,632	502,200	514,632
Other income		542,535	34,665	542,535	34,665
Interest income		143,782	38,688	143,782	38,688
		<u>7,870,532</u>	<u>7,864,352</u>	<u>7,870,532</u>	<u>7,864,352</u>
LESS: EXPENDITURE					
Staff costs	4	(2,299,563)	(2,086,716)	(2,299,563)	(2,086,716)
Research expenditure		(366,099)	(450,297)	(366,099)	(450,297)
Depreciation of property, plant and equipment		(890,224)	(1,003,550)	(890,224)	(1,003,550)
Loss on disposal of property, plant and equipment		(7,791)	-	(7,791)	-
Training expenditure		(73,517)	(65,982)	(73,517)	(65,982)
Repairs and maintenance expenditure		(24,236)	(48,282)	(24,236)	(48,282)
Professional fees		(75,629)	(170,651)	(75,629)	(170,651)
Travelling expenses		(56,571)	(48,489)	(56,571)	(48,489)
Computer related expenses		(40,852)	(41,507)	(40,852)	(41,507)
Seminar/conference expenses		(61,470)	(66,110)	(61,470)	(66,110)
Insurance expenses		(91,861)	(83,711)	(91,861)	(83,711)
Marketing and fund raising expenses		(154,241)	(308,768)	(154,241)	(308,768)
Cost of merchandise		(157,914)	-	(157,914)	-
Laboratory maintenance		(153,427)	(84,347)	(153,427)	(84,347)
Rental		(90,017)	(60,500)	(90,017)	(60,500)
Utilities		(54,224)	(20,269)	(54,224)	(20,269)
Purchase service		(357,496)	(892,733)	(357,496)	(892,733)
Dues and subscriptions		(25,720)	(21,993)	(25,720)	(21,993)
Motor vehicle expenses		(35,100)	(44,550)	(35,100)	(44,550)
Other expenses		(81,414)	(92,352)	(81,414)	(92,352)
		<u>(5,097,366)</u>	<u>(5,590,807)</u>	<u>(5,097,366)</u>	<u>(5,590,807)</u>
Reversal of impairment/(impairment) of investment in joint venture		11,447	(55,024)	-	(99,960)
Share of losses in a joint venture		(11,447)	(17,154)	-	-
EXCESS OF INCOME OVER EXPENDITURE		<u>2,773,166</u>	<u>2,201,367</u>	<u>2,773,166</u>	<u>2,173,585</u>

Company No.

510087	M
--------	---

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

STATEMENTS OF FINANCIAL POSITION AS AT 31 DECEMBER 2013

	Note	Economic Entity		Foundation	
		2013 RM	2012 RM	2013 RM	2012 RM
GENERAL FUND					
Balance at beginning of the financial year		9,849,606	7,648,239	9,849,606	7,676,021
Excess of income over expenditure		2,773,166	2,201,367	2,773,166	2,173,585
Balance at end of the financial year		<u>12,622,772</u>	<u>9,849,606</u>	<u>12,622,772</u>	<u>9,849,606</u>
Represented by:					
NON-CURRENT ASSETS					
Property, plant and equipment	6	4,835,154	4,635,474	4,835,154	4,635,474
Investment in joint venture	7	-	-	-	-
		<u>4,835,154</u>	<u>4,635,474</u>	<u>4,835,154</u>	<u>4,635,474</u>
CURRENT ASSETS					
Receivables	8	4,260,858	3,596,937	4,260,858	3,596,937
Cash and cash equivalents	9	5,927,739	4,617,966	5,927,739	4,617,966
		<u>10,188,597</u>	<u>8,214,903</u>	<u>10,188,597</u>	<u>8,214,903</u>
LESS: CURRENT LIABILITY					
Payables	10	422,746	689,338	422,746	689,338
		<u>422,746</u>	<u>689,338</u>	<u>422,746</u>	<u>689,338</u>
NET CURRENT ASSETS		<u>9,765,851</u>	<u>7,525,565</u>	<u>9,765,851</u>	<u>7,525,565</u>
NON-CURRENT LIABILITY					
Deferred income	11	1,978,233	2,311,433	1,978,233	2,311,433
NET ASSETS		<u>12,622,772</u>	<u>9,849,606</u>	<u>12,622,772</u>	<u>9,849,606</u>

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

STATEMENTS OF CHANGES IN GENERAL FUND FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013

	Note	Economic Entity		Foundation	
		2013 RM	2012 RM	2013 RM	2012 RM
As at 1 January		9,849,606	7,648,239	9,849,606	7,676,021
Excess of income over expenditure		2,773,166	2,201,367	2,773,166	2,173,585
At 31 December		<u>12,622,772</u>	<u>9,849,606</u>	<u>12,622,772</u>	<u>9,849,606</u>

Company No.

510087	M
--------	---

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company

limited by guarantee and not having a share capital)

STATEMENTS OF CASH FLOWS

FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013

	Note	Economic Entity		Foundation	
		2013 RM	2012 RM	2013 RM	2012 RM
OPERATING ACTIVITIES					
Excess of income over expenditure		2,773,166	2,201,367	2,773,166	2,173,585
Adjustments for non-cash movements:					
(Reversal of impairment)/impairment of investment in joint venture		(11,447)	55,024	-	99,960
Share of losses in a joint venture		11,447	17,154	-	-
Depreciation of property, plant and equipment		890,224	1,003,550	890,224	1,003,550
Loss on disposal of property, plant and equipment		7,791	-	7,791	-
Interest income		(143,782)	(38,688)	(143,782)	(38,688)
Impairment of investment in joint venture		-	55,024	-	99,960
		<u>3,527,399</u>	<u>3,238,407</u>	<u>3,527,399</u>	<u>3,238,407</u>
Changes in operating assets and liabilities:					
Increase in receivables		(663,921)	(3,051,340)	(663,921)	(3,051,340)
Decrease in payables		(266,592)	373,790	(266,592)	373,790
Decrease in deferred income		(333,200)	(437,200)	(333,200)	(437,200)
Net cash generated from operating activities		<u>2,263,686</u>	<u>123,657</u>	<u>2,263,686</u>	<u>123,657</u>
INVESTING ACTIVITIES					
Addition of investment in joint venture		-	(95,060)	-	(95,060)
Purchase of property, plant and equipment		(1,097,931)	(294,728)	(1,097,931)	(294,728)
Proceeds from disposal of property, plant and equipment		236	-	236	-
Interest income		143,782	38,688	143,782	38,688
Net cash used in investing activities		<u>(953,913)</u>	<u>(351,100)</u>	<u>(953,913)</u>	<u>(351,100)</u>
NET (DECREASE)/INCREASE IN CASH AND CASH EQUIVALENTS		<u>1,309,773</u>	<u>(227,443)</u>	<u>1,309,773</u>	<u>(227,443)</u>
CASH AND CASH EQUIVALENTS AT BEGINNING OF THE FINANCIAL YEAR		<u>4,617,966</u>	<u>4,845,409</u>	<u>4,617,966</u>	<u>4,845,409</u>
CASH AND CASH EQUIVALENTS AT END OF THE FINANCIAL YEAR	9	<u><u>5,927,739</u></u>	<u><u>4,617,966</u></u>	<u><u>5,927,739</u></u>	<u><u>4,617,966</u></u>

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013

GENERAL INFORMATION

The Foundation is a company incorporated and domiciled in Malaysia, limited by guarantee and does not have a share capital.

The principal activity of the Foundation is to receive and administer funds for cancer research purposes.

The Foundation's joint venture is principally involved in rendering of services and products based in cell biology and cell culture technology.

There have been no significant changes in the nature of this activity during the financial year.

The address of the registered office of the Foundation is as follows:

1st Floor Lot 33
Jalan Pelukis U1/46
Temasya Industrial Park
Seksyen U1
40150 Shah Alam
Selangor Darul Ehsan
Malaysia

The principal place of business of the Foundation is as follows:

2nd Floor, Outpatient Centre
Sime Darby Medical Centre Subang Jaya
47500 Subang Jaya
Selangor Darul Ehsan
Malaysia

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Unless otherwise stated, the following accounting policies have been applied consistently in dealing with items that are considered material in relation to the financial statements.

A BASIS OF PREPARATION

The financial statements of the Economic Entity and of the Foundation have been prepared in accordance with the provisions of the Malaysian Financial Reporting Standards ("MFRS"), International Financial Reporting Standards and the requirements of the Companies Act, 1965 in Malaysia.

The financial statements of the Economic Entity are the financial statements of the Foundation in which equity method of accounting has been applied to account for its investment in the joint venture.

The financial statements have been prepared under the historical cost convention except as disclosed in this summary of significant accounting policies.

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)****SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)****A BASIS OF PREPARATION (CONTINUED)**

The preparation of financial statements in conformity with MFRS requires the use of certain critical accounting estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of income and expenses during the reported period. It also requires the Trustees to exercise their judgement in the process of applying the Economic Entity's and the Foundation's accounting policies. Although these estimates and judgement are based on the Trustees' best knowledge of current events and actions, actual results may differ.

(a) Standards and amendments to published standards that are effective

The new accounting standards, amendments and improvements to published standards that are effective for the Economic Entity's and the Foundation's financial year beginning on or after 1 January 2013 are as follows:

- MFRS 11 'Joint arrangements'
- MFRS 12, 'Disclosures of Interests in Other Entities'
- MFRS 13, 'Fair Value Measurement'
- The revised MFRS 127, 'Separate Financial Statements'
- The revised MFRS 128, 'Investments in Associates and Joint Ventures'
- Amendments to MFRS 101 'Presentation of items of other comprehensive income'
- Amendment to MFRS 7, 'Financial Instruments: Disclosures'
- Amendments to MFRS 10, 11 and 12 'Consolidated Financial Statements, Joint Arrangements and Disclosure of Interests in Other Entities: Transition Guidance'
- Annual improvements 2009 – 2011 Cycle

The above standards, amendments and improvements to published standards did not have any significant impact on the financial statements of the Economic Entity and the Foundation.

(b) Standard early adopted by the Economic Entity and the Foundation

The amendments to MFRS 136 'Impairment of assets' removed certain disclosures of the recoverable amount of cash generating units which had been included in MFRS 136 by the issuance of MFRS 13. The amendment is not mandatory for the Economic Entity and the Foundation until 1 January 2014, however the Economic Entity and the Foundation have decided to early adopt the amendment as of 1 January 2013.

The adoption of the amendments to MFRS 136 did not have any significant impact on the financial statements of the Economic Entity and the Foundation.

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

A BASIS OF PREPARATION (CONTINUED)

- (c) Standard and amendment to published standard that are applicable to the Economic Entity and the Foundation but not yet effective

The Economic Entity and the Foundation will apply the new standard and amendment to published standard in the following period:

- (i) Financial period beginning on/after 1 January 2014
- Amendment to MFRS 132, 'Financial instruments: Presentation' (effective from 1 January 2014) does not change the current offsetting model in MFRS 132. It clarifies the meaning of 'currently has a legally enforceable right of set-off' that the right of set-off must be available today (not contingent on a future event) and legally enforceable for all counterparties in the normal course of business. It clarifies that some gross settlement mechanisms with features that are effectively equivalent to net settlement will satisfy the MFRS 132 offsetting criteria.
- (ii) Effective date yet to be determined by Malaysian Accounting Standards Board
- MFRS 9, 'Financial Instruments – Classification and Measurement of Financial Assets and Financial Liabilities' replaces the parts of MFRS 139 that relate to the classification and measurement of financial instruments. MFRS 9 requires financial assets to be classified into two measurement categories: those measured as at fair value and those measured at amortised cost. The determination is made at initial recognition. The classification depends on the entity's business model for managing its financial instruments and the contractual cash flow characteristics of the instrument. For financial liabilities, the standard retains most of the MFRS 139 requirements. The main change is that, in cases where the fair value option is taken for financial liabilities, the part of a fair value change due to an entity's own credit risk is recorded in other comprehensive income rather than the income statement, unless this creates an accounting mismatch. The Foundation has yet to assess the full impact of MFRS 9. The Foundation will also consider the impact of the remaining phases of MFRS 9 when completed by the Board.

The above standard and amendment to published standard are not anticipated to have any significant impact on the financial statements of the Economic Entity and of the Foundation in the period of initial adoption.

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

B DONATIONS AND RESEARCH GRANTS

Donations and research grants are recognised as income when the Economic Entity's and the Foundation's right to receive payment is established.

C OTHER INCOME

Interest income is recognised on a time proportion basis, taking into account the principal outstanding and the effective rate over the period to maturity, when it is determined that such income will accrue to the Economic Entity and the Foundation.

Income from advisory and consultancy service is recognised when the services are provided.

D PROPERTY, PLANT AND EQUIPMENT

Property, plant and equipment are stated at cost less accumulated depreciation and accumulated impairment loss.

Cost includes expenditure that is directly attributable to the acquisition of the asset. Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Economic Entity and the Foundation and the cost of the item can be measured reliably. The carrying amount of the replaced part is derecognised. All other repairs and maintenance expenses are recognised as expenses in the income and expenditure statements.

Property, plant and equipment are depreciated on a straight line basis to write-off the cost of the assets to their residual values over their estimated useful lives at the following annual depreciation rates, as summarised below:

Laboratory equipment	10.0%
Renovations	25.0%
Computers	33.3%
Office equipment	10.0%

The residual values and useful lives of property, plant and equipment are reviewed, and adjusted as appropriate, at the end of the reporting period. The effects of any revision of the residual values and useful lives are included in the income and expenditure statements for the financial year in which the changes arise.

At the end of each reporting period, the Economic Entity and the Foundation assess whether there is any indication of impairment. Where an indication of impairment exists, the carrying amount of the asset is assessed and written down immediately to its recoverable amount (see accounting policy E on impairment of non-financial assets).

Gains and losses on disposals are determined by comparing proceeds with carrying amounts and are included in the income and expenditure statements.

Company No.

510087	M
--------	---

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

E IMPAIRMENT OF NON-FINANCIAL ASSETS

Assets that are subject to amortisation are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount may not be recoverable. An impairment loss is recognised for the amount by which the carrying amount of the asset exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value-in-use. For the purposes of assessing impairment, assets are grouped at the lowest level for which there are separately identifiable cash flows (cash-generating units). Non-financial assets other than goodwill that suffered impairment are reviewed for possible reversal of the impairment at the end of each reporting date.

The impairment loss is charged to the income and expenditure statements and any subsequent increase in recoverable amount is recognised in the income and expenditure statements.

F GOVERNMENT GRANTS

Grants from the government are recognised at their fair values when there is a reasonable assurance that the grant will be received and the Economic Entity and the Foundation will comply with their attached conditions.

Government grants relating to costs are deferred and recognised in the income and expenditure statement over the period necessary to match them with the costs they are intended to compensate.

Government grants relating to the purchase of assets are included in non-current liabilities as deferred income and are credited to the income and expenditure statements on a straight line basis over the expected useful lives of the related assets.

G CASH AND CASH EQUIVALENTS

Cash and cash equivalents comprise cash and bank balances and demand deposits with original maturity of three months or less, that are readily convertible to known amounts of cash and are subject to an insignificant risk of changes in value.

H EMPLOYEE BENEFITS

Wages, salaries, paid annual leave and sick leave, bonuses, and non-monetary benefits are accrued in the period in which the associated services are rendered by employees of the Economic Entity and the Foundation.

The Economic Entity's and the Foundation's contributions to the Employees' Provident Fund are charged to the income and expenditure statement in the period to which they relate. Once the contributions have been paid, the Economic Entity and the Foundation have no further payment obligations.

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company

limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

I FINANCIAL ASSETS

(a) Classification

The Economic Entity and the Foundation classify the financial assets as loans and receivables. The classification depends on the purpose for which the financial assets were acquired. Management determines the classification at initial recognition.

Loans and receivables

Loans and receivables are non-derivative financial assets with fixed or determinable payments that are not quoted in an active market. They are included in current assets, except for maturities greater than 12 months after the end of the reporting period. These are classified as non-current assets. The Economic Entity's and the Foundation's loans and receivables comprise 'receivables' and 'cash and cash equivalents' in the statements of financial position (Note 8 and Note 9).

(b) Recognition and initial measurement

Regular purchases and sales of financial assets are recognised on the trade-date, the date on which the Economic Entity and the Foundation commit to purchase or sell the asset.

Financial assets are initially recognised at fair value plus transaction costs for all financial assets not carried at fair value through profit or loss.

(c) Subsequent measurement – gains and losses

Loans and receivables financial assets are subsequently carried at amortised cost using the effective interest method.

(d) Subsequent measurement - Impairment of financial assets

Assets carried at amortised cost

The Economic Entity and the Foundation assess at the end of the reporting period whether there is objective evidence that a financial asset or group of financial assets is impaired. A financial asset or a group of financial assets is impaired and impairment losses are incurred only if there is objective evidence of impairment as a result of one or more events that occurred after the initial recognition of the asset (a 'loss event') and that loss event (or events) has an impact on the estimated future cash flows of the financial asset or group of financial assets that can be reliably estimated.

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)****SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)****I FINANCIAL ASSETS (CONTINUED)****(d) Subsequent measurement - Impairment of financial assets (continued)**Assets carried at amortised cost (continued)

The criteria that the Economic Entity and the Foundation use to determine that there is objective evidence of an impairment loss include:

- Significant financial difficulty of the issuer or obligor;
- A breach of contract, such as a default or delinquency in interest or principal payments;
- The Economic Entity and the Foundation, for economic or legal reasons relating to the borrower's financial difficulty, granting to the borrower a concession that the lender would not otherwise consider;
- It becomes probable that the borrower will enter bankruptcy or other financial reorganisation;
- Disappearance of an active market for that financial asset because of financial difficulties; or
- Observable data indicating that there is a measurable decrease in the estimated future cash flows from a portfolio of financial assets since the initial recognition of those assets, although the decrease cannot yet be identified with the individual financial assets in the portfolio, including:
 - (i) adverse changes in the payment status of borrowers in the portfolio; and
 - (ii) national or local economic conditions that correlate with defaults on the assets in the portfolio.

The amount of the loss is measured as the difference between the asset's carrying amount and the present value of estimated future cash flows (excluding future credit losses that have not been incurred) discounted at the financial asset's original effective interest rate. The asset's carrying amount of the asset is reduced and the amount of the loss is recognised in the income and expenditure statements. If 'loans and receivables' has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract. As a practical expedient, the Economic Entity and the Foundation may measure impairment on the basis of an instrument's fair value using an observable market price.

If, in a subsequent period, the amount of the impairment loss decreases and the decrease can be related objectively to an event occurring after the impairment was recognised (such as an improvement in the debtor's credit rating), the reversal of the previously recognised impairment loss is recognised in the income and expenditure statements.

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

I FINANCIAL ASSETS (CONTINUED)

- (d) Subsequent measurement - Impairment of financial assets (continued)

Assets carried at amortised cost (continued)

When an asset is uncollectible, it is written off against the related allowance account. Such assets are written off after all the necessary procedures have been completed and the amount of the loss has been determined.

- (e) De-recognition

Financial assets are de-recognised when the rights to receive cash flows or have been transferred and the Economic Entity and the Foundation have transferred substantially all risks and rewards of ownership.

J JOINTLY ARRANGEMENTS

A joint arrangement is an arrangement of which there is contractually agreed sharing of control by the Foundation with one or more parties, where decisions about the relevant activities relating to the joint arrangement require unanimous consent of the parties sharing control. The classification of a joint arrangement as a joint operation or a joint venture depends upon the rights and obligations of the parties to the arrangement. A joint venture is a joint arrangement whereby the joint venturers have rights to the net assets of the arrangement. A joint operation is a joint arrangement whereby the joint operators have rights to the assets and obligations for the liabilities, relating to the arrangement.

The Foundation's interest in a joint venture is accounted for in the financial statements by the equity method of accounting. Under the equity method of accounting, interests in joint ventures are initially recognised at cost and adjusted thereafter to recognise the Foundation's share of the post-acquisition profits or losses and movements in other comprehensive income. When the Foundation's share of losses in a joint venture equals or exceeds its interests in the joint ventures (which includes any long-term interests that, in substance, form part of the Foundation's net investment in the joint ventures), the Foundation does not recognise further losses, unless it has incurred obligations or made payments on behalf of the joint ventures.

Unrealised gains on transactions between the Foundation and its joint ventures are eliminated to the extent of the Foundation's interest in the joint ventures. Unrealised losses are also eliminated unless the transaction provides evidence of an impairment of the asset transferred. Accounting policies of the joint ventures have been changed where necessary to ensure consistency with the policies adopted by the Foundation.

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONTINUED)

K Investments in subsidiaries, joint ventures and associates

In the Foundation's separate financial statements, investment in joint venture is carried at cost less accumulated impairment losses. On disposal of investment in joint venture, the difference between disposal proceeds and the carrying amounts of the investments are recognised in profit or loss.

L OFFSETTING FINANCIAL INSTRUMENTS

Financial assets and liabilities are offset and the net amount is presented in the statement of financial position when there is a legally enforceable right to offset the recognised amounts and there is an intention to settle on a net basis, or realise the asset and settle the liability simultaneously.

M CONTINGENT ASSETS AND CONTINGENT LIABILITIES

The Economic Entity and the Foundation do not recognise a contingent asset and liability but discloses its existence in the financial statements. A contingent liability is a possible obligation that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Economic Entity and the Foundation or a present obligation that is not recognised because it is not probable that an outflow of resources will be required to settle the obligation. A contingent liability also arises in the extremely rare circumstance where there is a liability that cannot be recognised because it cannot be measured reliably. However, contingent liabilities do not include financial guarantee contracts.

A contingent asset is a possible asset that arises from past events whose existence will be confirmed by the occurrence or non-occurrence of one or more uncertain future events beyond the control of the Economic Entity and the Foundation. The Economic Entity and the Foundation do not recognise contingent assets but discloses its existence where inflows or economic benefits are probable, but not virtually certain.

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)****FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES**

(i) Financial risk factors

(a) Credit risk

The management does not consider there to be any significant concentration of credit risk.

Credit quality of financial assets

Information regarding credit quality of other receivables is disclosed in Note 8. Deposits with banks and other financial institutions and investment securities are placed with or entered into with reputable financial institutions or companies with high credit ratings and no history of default.

Other receivables that are neither past due nor impaired are substantially companies with no history of default with the Economic Entity and the Foundation.

(b) Interest rate risk

The Economic Entity and the Foundation are subject to interest rate risk as the deposit with the licensed bank is interest-bearing. A 1% (2012: Nil) increase in the interest rate would result in an increase in the income and expenditure statements by RM56,000 (2012: Nil).

(c) Liquidity and cash flow risk

The Economic Entity and the Foundation adopt prudent liquidity risk management by maintaining sufficient cash resources and having available funding through donors. The Economic Entity's and the Foundation's operations are financed mainly through donations and research grants received.

The table below analyses the financial liabilities into relevant maturity groupings based on the remaining period at the reporting date to the contractual maturity date. The amounts disclosed in the table are the contractual undiscounted cash flows:

	<u>Economic Entity and Foundation</u>	
	<u>2013</u> RM	<u>2012</u> RM
<u>Less than 1 year</u>	422,746	689,338
Payables	<u>422,746</u>	<u>689,338</u>

CANCER RESEARCH INITIATIVES FOUNDATION
(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)

FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONTINUED)

(ii) Capital risk management

The Economic Entity's and the Foundation's objectives when managing capital are to safeguard the Economic Entity's and the Foundation's ability to continue as a going concern in order to provide returns for stakeholders and to maintain an optimal capital structure to reduce the cost of capital.

The Economic Entity and the Foundation regard the general fund as their capital.

(iii) Financial instruments by category

	<u>Economic Entity and Foundation</u>	
	<u>2013</u>	<u>2012</u>
	RM	RM
<u>Loan and receivables</u>		
<u>Current</u>		
Receivables (excluding prepayments)	4,204,441	3,586,390
Cash and bank balances	5,927,739	4,617,966
	<u>10,132,180</u>	<u>8,204,356</u>
<u>Other financial liabilities at amortised cost</u>		
<u>Current</u>		
Payables	<u>422,746</u>	<u>689,338</u>

STAFF COSTS

	<u>Economic Entity and Foundation</u>	
	<u>2013</u>	<u>2012</u>
	RM	RM
Salary, wages and overtime	1,818,439	1,762,226
Defined contribution plan	269,749	220,228
Other employee benefits	211,375	104,262
	<u>2,299,563</u>	<u>2,086,716</u>

TAXATION

No provision has been made for taxation as the Foundation is a charitable institution which is exempted from tax by virtue of Section 127 (1) of the Income Tax Act, 1967 (Paragraph 13(1)(a) of Schedule 6).

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION
 (Company No. 510087-M)
 (Incorporated in Malaysia as a company
 limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
 FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)**

6 **PROPERTY, PLANT AND EQUIPMENT**

Economic Entity and Foundation

	<u>Laboratory equipment</u> RM	<u>Renovations</u> RM	<u>Computers</u> RM	<u>Office equipment</u> RM	<u>Total</u> RM
2013					
<u>Cost</u>					
At 1 January 2013	10,970,439	650,781	696,645	99,763	12,417,628
Additions	813,773	173,988	38,525	71,645	1,097,931
Disposals	(2,069,280)	-	(29,157)	(1,498)	(2,099,935)
At 31 December 2013	<u>9,714,932</u>	<u>824,769</u>	<u>706,013</u>	<u>169,910</u>	<u>11,415,624</u>
<u>Accumulated depreciation</u>					
At 1 January 2013	6,523,107	621,079	586,306	51,662	7,782,154
Depreciation charge for the financial year	771,533	41,470	66,795	10,426	890,224
Disposals	(2,062,310)	-	(29,157)	(441)	(2,091,908)
At 31 December 2013	<u>5,232,330</u>	<u>662,549</u>	<u>623,944</u>	<u>61,647</u>	<u>6,580,470</u>
<u>Net book value</u>					
At 31 December 2013	<u><u>4,482,602</u></u>	<u><u>162,220</u></u>	<u><u>82,069</u></u>	<u><u>108,263</u></u>	<u><u>4,835,154</u></u>
2012					
<u>Cost</u>					
At 1 January 2012	10,748,082	650,781	627,424	96,613	12,122,900
Additions	222,357	-	69,221	3,150	294,728
At 31 December 2012	<u>10,970,439</u>	<u>650,781</u>	<u>696,645</u>	<u>99,763</u>	<u>12,417,628</u>
<u>Accumulated depreciation</u>					
At 1 January 2012	5,658,561	560,624	514,691	44,728	6,778,604
Depreciation charge for the financial year	864,546	60,455	71,615	6,934	1,003,550
At 31 December 2012	<u>6,523,107</u>	<u>621,079</u>	<u>586,306</u>	<u>51,662</u>	<u>7,782,154</u>
<u>Net book value</u>					
At 31 December 2012	<u><u>4,447,332</u></u>	<u><u>29,702</u></u>	<u><u>110,339</u></u>	<u><u>48,101</u></u>	<u><u>4,635,474</u></u>

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)****INVESTMENT IN JOINT VENTURE**

	<u>Economic Entity</u>		<u>Foundation</u>	
	<u>2013</u> RM	<u>2012</u> RM	<u>2013</u> RM	<u>2012</u> RM
Unquoted shares in Malaysia, at cost	99,960	99,960	99,960	99,960
Add: Share of post-acquisition results and reserve	(56,383)	(44,936)	-	-
	43,577	55,024	99,960	99,960
Less: Accumulated impairment loss	(43,577)	(55,024)	(99,960)	(99,960)
	-	-	-	-

The joint venture listed below has share capital consisting solely of ordinary shares, which is held directly by the Foundation.

<u>Name of company</u>	<u>Place of incorporation</u>	<u>Principal activities</u>	<u>Foundation's effective interest</u>	
			<u>2013</u> %	<u>2012</u> %
AseaCyte Sdn. Bhd.	Malaysia	Rendering of services and products based in cell biology and cell culture technology	49.00	49.00

AseaCyte Sdn. Bhd. grants the Foundation 5 year royalty-free license for access to its cell biology and cell culture technology from 12 February 2010 to 11 February 2015.

The joint venture is a private company and there is no quoted market price available for its shares.

There are no commitments or contingent liabilities relating to the Foundation's interest in the joint venture.

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION
 (Company No. 510087-M)
 (Incorporated in Malaysia as a company
 limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
 FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)**

INVESTMENT IN JOINT VENTURE (CONTINUED)

Set out below are the summarised financial information for AseaCyte Sdn. Bhd. which is accounted for using the equity method.

(a) Summarised statement of financial position

	<u>Economic Entity</u>	
	<u>2013</u> RM	<u>2012</u> RM
NON-CURRENT ASSET	4,092	6,648
CURRENT ASSETS		
Cash and cash equivalent	61,049	45,089
Other current assets	73,831	148,712
	<u>134,880</u>	<u>193,801</u>
CURRENT LIABILITIES		
Other current liabilities	(50,040)	(88,156)
Net current assets	<u>84,840</u>	<u>105,645</u>
Net assets	<u><u>88,932</u></u>	<u><u>112,293</u></u>

(b) Summarised statement of comprehensive income

	<u>Economic Entity</u>	
	<u>2013</u> RM	<u>2012</u> RM
Revenue	242,699	260,219
Depreciation and amortisation	(2,556)	(1,336)
Other operating expense	(263,504)	(293,893)
	<u>(23,361)</u>	<u>(35,010)</u>
Loss before tax	-	-
Income tax expense	(23,361)	(35,010)
Loss after tax	<u><u>(23,361)</u></u>	<u><u>(35,010)</u></u>

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company

limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)**

INVESTMENT IN JOINT VENTURE (CONTINUED)

(c) Reconciliation of summarised financial information

The reconciliation between the summarised financial information and the carrying amount of the joint venture are as follows:

	<u>Economic Entity</u>	
	<u>2013</u>	<u>2012</u>
	RM	RM
Opening net assets/(liabilities)	112,293	(46,697)
Issuance of share capital	-	194,000
Loss for the period	(23,361)	(35,010)
Closing net assets	<u>88,932</u>	<u>112,293</u>
Share of net assets in joint venture	43,577	55,024
Accumulated impairment loss	(43,577)	(55,024)
Carrying amount of investment in joint venture	<u>-</u>	<u>-</u>

The Foundation has fully impaired the carrying value of the investment in the joint venture on the basis that they will be discontinuing with this joint venture arrangement.

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company

(limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)**

RECEIVABLES

	<u>Economic Entity and Foundation</u>	
	<u>2013</u>	<u>2012</u>
	RM	RM
Deposits	38,610	18,710
Prepayment	56,417	10,547
Other receivables	4,165,831	3,567,680
	<u>4,260,858</u>	<u>3,596,937</u>

Other receivables comprise the donations which have not been received as at the reporting date.

As at 31 December 2013, the other receivables balance can be analysed as follows:

	<u>Economic Entity and Foundation</u>	
	<u>2013</u>	<u>2012</u>
	RM	RM
<u>Other receivables:</u>		
- Current	4,006,224	2,977,082
- Past due		
61-90 days	-	590,598
Over 180 days	159,607	-
	<u>4,165,831</u>	<u>3,596,937</u>

The other receivables which were past due but not impaired relate to a number of independent customers for whom there is no recent history of default.

The other classes within trade and other receivables do not contain impaired assets.

The maximum exposure to credit risk at the reporting date is the carrying value of each class of receivables mentioned above. The Economic Entity and the Foundation do not hold any collateral as security.

Company No.

510087	M
--------	---

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)**

9 CASH AND CASH EQUIVALENTS

	<u>Economic Entity and Foundation</u>	
	<u>2013</u>	<u>2012</u>
	RM	RM
Deposits with licensed bank	5,600,000	-
Bank balances	323,739	4,613,966
Cash on hand	4,000	4,000
	<u>5,927,739</u>	<u>4,617,966</u>

The deposits with licensed bank carry interest rates range from 3.00% to 3.05% (2012: nil) per annum as at the reporting date and have maturity periods range from one to three months (2012: nil).

10 PAYABLES

	<u>Economic Entity and Foundation</u>	
	<u>2013</u>	<u>2012</u>
	RM	RM
Accruals	348,956	689,338
Other payables	73,790	-
	<u>422,746</u>	<u>689,338</u>

11 DEFERRED INCOME

The Economic Entity and the Foundation obtained a government grant of RM3,500,000 in the financial year ended 31 December 2008 and were required to utilise the funds for certain projects and activities, including the acquisition of certain assets, as approved and prescribed under the terms of the grant. Government grant relating to the purchase of assets is credited to the income and expenditure statements on a straight line basis over the expected useful lives of the related assets. Government grant relating to costs is recognised in the income and expenditure statements over the periods to match the related costs for which the grants are intended to compensate.

	<u>Economic Entity and Foundation</u>	
	<u>2013</u>	<u>2012</u>
	RM	RM
At 1 January	2,311,433	2,748,633
Credited to income and expenditure statement	(333,200)	(437,200)
At 31 December	<u>1,978,233</u>	<u>2,311,433</u>

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

**NOTES TO THE FINANCIAL STATEMENTS
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2013 (CONTINUED)**

12 APPROVAL OF FINANCIAL STATEMENTS

The financial statements have been approved for issue in accordance with a resolution of the Board of Trustees dated 22 May 2014.

Company No.

510087

M

CANCER RESEARCH INITIATIVES FOUNDATION
(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)


**STATEMENT BY TRUSTEES PURSUANT TO
SECTION 169(15) OF THE COMPANIES ACT, 1965**

We, Tunku Tan Sri Dato' Seri Ahmad bin Tunku Yahaya and Toh Puan Dato' Seri Hajah Dr Aishah Ong, being two of the Trustees of Cancer Research Initiatives Foundation, do hereby state that, in the opinion of the Trustees, the financial statements set out on pages 4 to 25 are drawn up so as to give a true and fair view of the state of affairs of the Economic Entity and of the Foundation as at 31 December 2013 and of its results and cash flows for the financial year ended on that date in accordance with the Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act, 1965 in Malaysia.

Signed in accordance with the resolution of the Board of Trustees dated 22 May 2014.




TUNKU TAN SRI DATO' SERI AHMAD
BIN TUNKU YAHAYA
TRUSTEE



TOH PUAN DATO' SERI HAJAH
DR AISHAH ONG
TRUSTEE

**STATUTORY DECLARATION PURSUANT TO
SECTION 169(16) OF THE COMPANIES ACT, 1965**

I, Tunku Tan Sri Dato' Seri Ahmad bin Tunku Yahaya, the Trustee primarily responsible for the financial management of Cancer Research Initiatives Foundation, do solemnly and sincerely declare that the financial statements set out on pages 4 to 25 are, in my opinion, correct and I make this solemn declaration conscientiously believing the same to be true, and by virtue of the provisions of the Statutory Declarations Act 1960.




TUNKU TAN SRI DATO' SERI AHMAD
BIN TUNKU YAHAYA

Subscribed and solemnly declared by the above named Tunku Tan Sri Dato' Seri Ahmad bin Tunku Yahaya at ~~Selangor~~ ~~Jaya~~, Malaysia on 22 May 2014.

Before me, **Kuala Lumpur**



COMMISSIONER FOR OATHS



Suite 5.1A, 5th Flr., Wisma Sime Darby
Jalan Raja Laut
50350 Kuala Lumpur



PWC

**INDEPENDENT AUDITORS' REPORT TO THE MEMBERS
OF CANCER RESEARCH INITIATIVES FOUNDATION**

(Company No. 510087-M)

(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

REPORT ON THE FINANCIAL STATEMENTS

We have audited the financial statements of Cancer Research Initiatives Foundation, which comprise the statements of financial position as at 31 December 2013 of the Economic Entity and of the Foundation and the income and expenditure statements, statements of changes in general fund and statements of cash flows for the financial year then ended of the Economic Entity and of the Foundation, and a summary of significant accounting policies and other explanatory information, as set out on pages 4 to 25.

Trustees' Responsibility for the Financial Statements

The Trustees of the Foundation are responsible for the preparation of financial statements so as to give a true and fair view in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards and the requirements of the Companies Act, 1965 in Malaysia. The Trustees of the Foundation are also responsible for such internal control as the Trustees determine are necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

Auditors' Responsibility

Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our audit in accordance with approved standards on auditing in Malaysia. Those standards require that we comply with ethical requirements and plan and perform the audit to obtain reasonable assurance about whether the financial statements are free from material misstatement.

An audit involves performing procedures to obtain audit evidence about the amounts and disclosures in the financial statements. The procedures selected depend on our judgement, including the assessment of risks of material misstatement of the financial statements, whether due to fraud or error. In making those risk assessments, we consider internal control relevant to the Foundation's preparation of financial statements that give a true and fair view in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Foundation's internal control. An audit also includes evaluating the appropriateness of accounting policies used and the reasonableness of accounting estimates made by the Trustees, as well as evaluating the overall presentation of the financial statements.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

*PricewaterhouseCoopers (AF 1146), Chartered Accountants,
Level 10, 1 Sentral, Jalan Travers, Kuala Lumpur Sentral, P.O. Box 10192, 50706 Kuala Lumpur, Malaysia
T: +60 (3) 2173 1188. F: +60 (3) 2173 1288, www.pwc.com/my*



INDEPENDENT AUDITORS' REPORT TO THE MEMBERS
OF CANCER RESEARCH INITIATIVES FOUNDATION (CONTINUED)
(Company No. 510087-M)
(Incorporated in Malaysia as a company
limited by guarantee and not having a share capital)

REPORT ON THE FINANCIAL STATEMENTS (CONTINUED)

Opinion

In our opinion, the financial statements give a true and fair view of the financial position of the Economic Entity and of the Foundation as of 31 December 2013 and of their financial performance and cash flows for the financial year then ended in accordance with Malaysian Financial Reporting Standards, International Financial Reporting Standards the requirements of the Companies Act, 1965 in Malaysia.

REPORT ON OTHER LEGAL AND REGULATORY REQUIREMENTS

In accordance with the requirements of the Companies Act, 1965 in Malaysia, we also report that, in our opinion, the accounting and other records and the registers required by the Act to be kept by the Foundation have been properly kept in accordance with the provisions of the Act.

OTHER MATTERS

This report is made solely to the members of the Foundation, as a body, in accordance with Section 174 of the Companies Act, 1965 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the content of this report.

PRICEWATERHOUSECOOPERS
(No. AF: 1146)
Chartered Accountants

I.O.H. LAY CHOON
(No. 2497/03/16(J))
Chartered Accountant

Kuala Lumpur
22 May 2014